Profound Medical (PROF) Cash from Operations Growth (3y) (2021 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.82 Bn | 146.17 Bn | 6.27 Bn | 4.78% |
| 2 | Stryker | 115.07 Bn | 112.19 Bn | 3.81 Bn | 9.30% |
| 3 | Medtronic | 95.25 Bn | 87.08 Bn | 5.76 Bn | 20.35% |
| 4 | Boston Scientific | 71.38 Bn | 70.17 Bn | 3.61 Bn | 22.35% |
| 5 | Edwards Lifesciences | 51.08 Bn | 47.41 Bn | 1.29 Bn | -48.14% |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn | 0.50% |
| 7 | Dexcom | 28.84 Bn | 27.72 Bn | 750.30 Mn | 50.11% |
| 8 | GE HealthCare Technologies | 28.56 Bn | 26.49 Bn | 1.98 Bn | -14.75% |
| 9 | Steris | 20.71 Bn | 20.30 Bn | 697.10 Mn | 15.83% |
| 10 | Profound Medical | 244.28 Mn | 193.99 Mn | 3.83 Mn | -51.45% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -51.45% |
| Dec 31, 2025 | 47.35% |
| Sep 30, 2025 | -54.26% |
| Jun 30, 2025 | -38.31% |
| Mar 31, 2025 | -1.77% |
| Dec 31, 2024 | 47.08% |
| Sep 30, 2024 | -30.66% |
| Jun 30, 2024 | -1.11% |
| Mar 31, 2024 | -39.63% |
| Dec 31, 2023 | 29.11% |
| Sep 30, 2023 | 0.11% |
| Jun 30, 2023 | -50.11% |
| Mar 31, 2023 | 45.39% |
| Dec 31, 2022 | -70.87% |
| Sep 30, 2022 | 62.42% |
| Jun 30, 2022 | 86.92% |
| Mar 31, 2022 | -48.09% |
| Dec 31, 2021 | -17.57% |